Core Viewpoint - The company is focusing on high-quality development and actively responding to changes in industry policies and market conditions, aiming to improve operational efficiency and management indicators [1] Financial Performance - In the first half of 2025, the company's operating revenue was 429 million yuan, and the net profit attributable to shareholders was 30.10 million yuan [1] - The net cash flow from operating activities was 17.88 million yuan, achieving a positive turnaround with a year-on-year growth of 364.33% [1] - The overall gross profit margin in the first half of 2025 increased compared to the entire year of 2024 [1] Strategic Initiatives - The company is committed to exploring market potential, strengthening cost control, and enhancing internal management to stabilize and improve operational management indicators [1]

Group 1 - The company announced on August 28 that its products have been exported to 32 countries and regions, including the United States and Canada, with various dosage forms such as concentrated pills, granules, tablets, and capsules [1] - Since passing the Australian TGA GMP inspection in 1996, the company has become one of the first Chinese traditional medicine enterprises to obtain PIC/S quality system certification and has received multiple international GMP certifications, including from the Australian TGA and Japan's Ministry of Health [1] - The company has achieved a total of 1,442 overseas product registrations and maintains a leading position in the industry regarding the number of foreign certifications, overseas trademark registrations, export coverage, and variety of products [1] Group 2 - The company plans to continue expanding its overseas market presence and deepen international cooperation by leveraging its export advantages through brand building and channel sharing to increase its international market share [1]

Financial Performance - In the first half of 2025, the company's revenue reached 3,010.46 million CNY, with a net profit attributable to shareholders of 42.9 million CNY, and a net cash flow from operating activities of 1,788.09 million CNY, achieving a year-on-year growth of 364.33% [2][4] - The overall gross margin for the first half of 2025 increased to 39.93%, up by 5.32% compared to the same period last year [3][7] Sales Channels and Market Strategy - The company maintained over 60% sales from commercial chains, approximately 20% from medical channels, and around 20% from online and other channels, with overall sales performance remaining stable compared to the previous year [4] - The company is leveraging e-commerce platforms like JD and Tmall to enhance market share and develop potential markets [4] Product Development and Innovation - The company is focusing on the secondary development of four unique products, including the Ren Shen Gu Ben Wan and Fu Fang Huang Qi Jian Pi Oral Liquid, aiming to enhance their market competitiveness through technological upgrades [6] - Major products with strong sales in the first half of 2025 include Liu Wei Di Huang Wan, Er Chen Wan, and An Gong Niu Huang Wan, with plans to continue promoting these key products [5] International Expansion - The company has exported products to 32 countries and regions, including the USA, Canada, and Australia, and has achieved significant international certifications, including TGA and PIC/S [8] - Future plans include increasing international market share through brand collaboration and channel sharing [8] Cost Management and Future Planning - The decrease in sales expenses is attributed to a decline in revenue and effective cost control measures implemented by the company [8] - The company is actively developing its "14th Five-Year Plan," focusing on marketing breakthroughs, brand building, and innovation in research and development [8]

Core Viewpoint - 佛慈制药 reported a decline in revenue amidst an overall downturn in the pharmaceutical manufacturing industry, but achieved significant growth in operating cash flow and maintained a strong net asset growth rate [1][2] Group 1: Financial Performance - The company's revenue for the first half of 2025 was 429 million yuan, a decrease compared to the same period last year [1] - Net profit attributable to shareholders was 30.1 million yuan, with operating cash flow turning positive at 17.88 million yuan, representing a year-on-year growth of 364.33% [1] - The average year-on-year growth rate of net assets was 2.69%, positioning the company at the top level within the industry [1] Group 2: Business Strategy - The pharmaceutical sector remains the primary revenue source for 佛慈制药, accounting for 99.85% of total income [1] - The company is optimizing its marketing structure and market layout, focusing on channel development and management to enhance product market share [1] - Key strategies include expanding market presence in various regions, integrating online and offline sales channels, and strengthening management through a comprehensive oversight system [1] Group 3: Brand and Product Development - 佛慈制药 is actively advancing brand building and has received multiple industry accolades, including recognition in the first batch of China's consumer brand list [2] - The company is progressing in new drug development, with three ancient classic formulas under development and one product entering non-clinical safety evaluation [2] - Future plans include a focus on large product development strategies, enhancing market share of traditional products, and increasing sales of exclusive varieties [2]

Core Insights - Lanzhou Foci Pharmaceutical Co., Ltd. reported a revenue of 429 million yuan and a net profit of 30.1 million yuan for the first half of 2025 [1] - The company is a key player in the traditional Chinese medicine industry in Northwest China, with a history dating back to 1929 and recognized as a "Chinese Time-honored Brand" [1] - Foci Pharmaceutical has a strong product portfolio with 467 drug approval numbers and 10 exclusive national products, contributing to its position among the top ten Chinese traditional medicine exporters [1] Group 1 - The company is focusing on high-quality development by exploring market potential, enhancing cost control, improving operational efficiency, and refining internal management [1] - Foci Pharmaceutical is optimizing its marketing structure and market layout, strengthening channel development and management to increase product market share [2] - The company is expanding its market coverage in South China, East China, North China, Southwest China, and overseas while consolidating its existing market in Northwest China [2] Group 2 - The company is leveraging e-commerce platforms like JD and Tmall to enhance online and offline sales integration, further boosting market share [2] - Foci Pharmaceutical is advancing the R&D of three ancient classic prescriptions as new drugs, with one already in non-clinical safety evaluation and the others in laboratory process research [2] - The company is also focusing on the secondary development of major products and integrating traditional Chinese medicine with health consumption trends to build momentum for long-term growth [2]

（2025年1月1日至2025年6月30日止） | 目 录 | 页 次 | | --- | --- | | 一、财务报表 | | | 合并资产负债表 | 1-2 | | 合并利润表 | 3 | | 合并现金流量表 | 4 | | 合并所有者权益变动表 | 5-6 | | 母公司资产负债表 | 7-8 | | 母公司利润表 | 9 | | 母公司现金流量表 | 10 | | 母公司所有者权益变动表 | 11-12 | | 二、财务报表附注 | 13-95 | 合并资产负债表 2025年6月30日 编制单位：兰州佛慈制药股份有限公司 金额单位：人民币元 | 项 目 | 注释 | 2025年6月30日 | 2025年1月1日 | | --- | --- | --- | --- | | 流动资产： | | | | | 货币资金 | 五、1 | 384,119,508.08 | 397,893,224.19 | | 交易性金融资产 | | | | | 衍生金融资产 | | | | | 应收票据 | 五、2 | 88,032,040.23 | 68,049,181.58 | | 应收账款 | 五、3 | 338,386, ...

兰州佛慈制药股份有限公司 2025 半年度非经营性资金占用及其他关联资金往来情况汇总表 | 甘肃佛慈健康生物科技股 | 受同一母公司 | 应收 | | 450.00 | | 450.00 | 销售货物 | 经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 份有限公司 | 控制 | | | | | | | | | 陕西佛慈医药有限公司 | 受同一母公司 | 应收 | 44,796,730.61 | 13,155,286.33 | 6,743,319.07 | 51,208,697.87 | 销售货物 | 经营性往来 | | | 控制 | | | | | | | | | 兰州佛慈伟业医药有限责 | 受同一母公司 | 应收 | 8,606,369.34 | 7,918,024.59 | 8,095,977.83 | 8,428,416.10 | 销售货物 | 经营性往来 | | 任公司 | 控制 | | | | | | | | | 兰州佛慈西城药业集团有 | 受同一母公司 | 应收 | 6,239,790.33 | 57,477,52 ...

证券代码：002644 证券简称：佛慈制药 公告编号：2025-020 兰州佛慈制药股份有限公司 第八届董事会第八次会议决议公告 兰州佛慈制药股份有限公司（以下简称"公司"）第八届董事会第八次会议于 2025 年 8 月 26 日 9:30 在公司五楼会议室以现场与通讯表决相结合的方式召开， 会议由董事长单小东先生主持。会议通知于 2025 年 8 月 22 日以书面、电子邮件、 电话等方式送达。会议应出席董事 6 人，实际出席董事 6 人。公司高级管理人员 列席会议。本次会议的召开符合《公司法》《公司章程》《董事会议事规则》及 有关法律法规的规定。 二、董事会会议审议情况 与会董事经过审议，通过以下议案： 1.审议通过了《2025 年半年度报告及报告摘要》 《2025 年半年度报告及报告摘要》详见 2025 年 8 月 27 日《证券时报》《证 券日报》及巨潮资讯网（www.cninfo.com.cn）。 本议案已经董事会审计委员会审议通过。 表决结果：6 票同意，0 票反对，0 票弃权。 2.审议通过了《关于经理层经营业绩责任书的议案》 同意公司经理层《任期经营业绩责任书（2025 年—2027 年）》《 ...

格隆汇8月26日丨佛慈制药(002644.SZ)公布2025年半年度报告，上半年公司实现营业收入4.29亿元，同 比下降13.93%；归属于上市公司股东的净利润3010.46万元，同比下降16.60%；归属于上市公司股东的 扣除非经常性损益的净利润2085.09万元，同比下降24.91%；基本每股收益0.0590元。 ...

兰州佛慈制药股份有限公司 2025 年半年度报告全文 兰州佛慈制药股份有限公司 2025 年半年度报告 2025 年 8 月 1 兰州佛慈制药股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 公司负责人单小东、主管会计工作负责人岳金风及会计机构负责人(会计 主管人员)王凌声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 公司在本报告"第三节 管理层讨论与分析"中分析了公司未来发展可能 面临的风险因素和应对措施，敬请投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 兰州佛慈制药股份有限公司 2025 年半年度报告全文 备查文件目录 一、载有公司法定代表人、主管会计工作负责人、会计机构负责人签名并盖章的财务报表； 二、报告期内在中国证监会指定信息披露媒体上披露过的所有公司文件的正本及公告的原稿。 4 兰州佛慈制药股份有限公司 2025 年半年度报告全文 2 | | 1 œ ...